Gluconate sodium
Based on 1 Customer Validation
Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury.
For research use only. We do not sell to patients.
- Purity : ≥98.0%
- CAS No.: 527-07-1
- Formula: C6H11NaO7
- Molecular Weight:218.14
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
All Endogenous Metabolite Isoforms
More
Biological Activity
Description
IC50 & Target
|
Human Endogenous Metabolite |
In Vitro
Gluconate sodium (0.5-3 mM; 5 min) inhibits thrombin-induced arachidonic acid peroxidation and superoxide anion production in platelets, reduces platelet protein oxidation/nitration, and decreases carbonyl group generation, thiol oxidation, and nitrotyrosine formation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Gluconate sodium (50 mg/kg body weight; once a day for 5 weeks) regulates the changes in hematological parameters induced by Dimethylhydrazine (HY-W460407) in mice, reduces the levels of lipid peroxidation and nitric oxide (NO) in colon tissues, and improves the pathological changes of colon tissues[3].
Gluconate sodium (2500 ppm; in diet; p.o.; 15 days) increases the average daily gain of weaned piglets, reduces the feed-to-gain ratio, alleviates the intestinal injury induced by recombinant Escherichia coli, and improves the intestinal morphology[4].
Gluconate sodium (Calcium gluconate; 50 mg/kg; p.o.; 84 days) alleviates the symptoms of osteoarthritis induced by anterior cruciate ligament transection and partial medial meniscectomy in Sprague-Dawley rats, and inhibits joint stiffness and cartilage damage[5].
Gluconate sodium (Calcium gluconate; 12.5-50 mg/kg; i.p.; 30 min after modeling) alleviates lipopolysaccharide (LPS)-induced acute lung injury in mice, and inhibits the infiltration of inflammatory cells and the release of inflammatory cytokines[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6J mice (4-6 weeks); acute lung injury model induced by lipopolysaccharide[6]
-
Dosage:12.5, 25, 50 mg/kg
-
Administration:Intraperitoneally injected, 30 min after modeling
-
Result:Inhibited airway inflammatory injury and the release of inflammatory cytokines such as IL-1β, IL-6, and TNF-α in bronchoalveolar lavage fluid.
Inhibited ERK phosphorylation, protecting the mouse airway from LPS-induced inflammatory response.
Chemical Information
-
CAS No. 527-07-1
-
Appearance Solid
-
Molecular Weight 218.14
-
Formula C6H11NaO7
-
SMILES
O[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)C(O[Na])=O
-
Synonyms
D-Gluconic acid sodium salt; Sodium D-gluconate; D-Gluconate sodium salt
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
H2O : ≥ 100 mg/mL (458.42 mM)
DMSO : 1 mg/mL (4.58 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (229.21 mM); Clear solution; Need ultrasonic
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Inhalation Toxicity Study
Inhalation toxicity studies expose rodents to a controlled aerosol, vapor, gas, or smoke atmosphere and assess respiratory and systemic toxicity using exposure-atmosphere characterization, clinical observations, body and organ weights, bronchoalveolar lavage fluid, histopathology, blood chemistry, hematology, and, when included, molecular endpoints such as transcriptomics, proteomics, lipidomics, or tissue burden analysis. The primary biological readouts are airway irritation, pulmonary inflammation, cytotoxicity, altered surfactant or lipid homeostasis, impaired particle clearance, and tissue remodeling, reflected by BALF cell differentials, BALF protein, LDH, phosphatase activities, cytokines, lung weight, microscopic respiratory-tract lesions, and retained lung burden.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Saluk-Juszczak J. A comparative study of antioxidative activity of calcium-D-glucarate, sodium-D-gluconate and D-glucono-1,4-lactone in a human blood platelet model. Platelets. 2010;21(8):632-40. [Content Brief]
[2]. Kameue C, et al. Dietary sodium gluconate protects rats from large bowel cancer by stimulating butyrate production. J Nutr. 2004 Apr;134(4):940-4. [Content Brief]
[3]. Saleem TH, et al. Possible Protective Effects of Quercetin and Sodium Gluconate Against Colon Cancer Induction by Dimethylhydrazine in Mice. Asian Pac J Cancer Prev. 2015;16(14):5823-8. [Content Brief]
[4]. Zhang Y, et al. Dietary supplementation with sodium gluconate improves the growth performance and intestinal function in weaned pigs challenged with a recombinant Escherichia coli strain. BMC Vet Res. 2022 Aug 6;18(1):303. [Content Brief]
[5]. Kang SJ, et al. Protective effects of calcium gluconate on osteoarthritis induced by anterior cruciate ligament transection and partial medial meniscectomy in Sprague-Dawley rats. J Orthop Surg Res. 2014 Mar 7;9(1):14. [Content Brief]
[6]. Liu L, et al. Effects of calcium gluconate on lipopolysaccharide-induced acute lung injury in mice. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2931-2935. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 4.5842 mL | 22.9211 mL | 45.8421 mL | 114.6053 mL |
| H2O | 5 mM | 0.9168 mL | 4.5842 mL | 9.1684 mL | 22.9211 mL |
| 10 mM | 0.4584 mL | 2.2921 mL | 4.5842 mL | 11.4605 mL | |
| 15 mM | 0.3056 mL | 1.5281 mL | 3.0561 mL | 7.6404 mL | |
| 20 mM | 0.2292 mL | 1.1461 mL | 2.2921 mL | 5.7303 mL | |
| 25 mM | 0.1834 mL | 0.9168 mL | 1.8337 mL | 4.5842 mL | |
| 30 mM | 0.1528 mL | 0.7640 mL | 1.5281 mL | 3.8202 mL | |
| 40 mM | 0.1146 mL | 0.5730 mL | 1.1461 mL | 2.8651 mL | |
| 50 mM | 0.0917 mL | 0.4584 mL | 0.9168 mL | 2.2921 mL | |
| 60 mM | 0.0764 mL | 0.3820 mL | 0.7640 mL | 1.9101 mL | |
| 80 mM | 0.0573 mL | 0.2865 mL | 0.5730 mL | 1.4326 mL | |
| 100 mM | 0.0458 mL | 0.2292 mL | 0.4584 mL | 1.1461 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.